Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.

doi:10.1053/j.gastro.2024.05.032

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.

Gastroenterology - 1 Oct 2024

Boilève Alice, Cartry Jérôme, Goudarzi Negaar, Bedja Sabrina, Mathieu Jacques R R, Bani Mohamed-Amine, Nicolle Rémy, Mouawia Ali, Bouyakoub Ryme, Nicotra Claudio, Ngo-Camus Maud, Job Bastien, Lipson Karélia, Boige Valérie, Valéry Marine, Tarabay Anthony, Dartigues Peggy, Tselikas Lambros, de Baere Thierry, Italiano Antoine, Cosconea Simona, Gelli Maximiliano, Fernandez-de-Sevilla Elena, Annereau Maxime, Malka David, Smolenschi Cristina, Ducreux Michel, Hollebecque Antoine, Jaulin Fanny

Abstract excerpt

BACKGROUND & AIMS: Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims to evaluate whether PDOs can be implemented in clinical practice to benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Biomarkers, Tumor

Share to Carcinoma, Pancreatic Ductal

Share to Organoids

Share to Pancreatic Neoplasms

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Open in PubMed

Identifiers

PMID: 38866343
DOI: 10.1053/j.gastro.2024.05.032

Genes

CDKN2A
EGFR
KRAS
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.PMID 38866343Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Pancreatic cancer patient-derived organoids capture therapy response and tumor evolutionSemantic proximity Read ↗

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read ↗

Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma PatientsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy.Semantic proximity Read ↗

The application of organoids in treatment decision-making for digestive system cancers: progress and challengesSemantic proximity Read ↗

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma TumorsSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.